Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,341 total articles
Clorox (CLX) trades on a sensible P/E, yields ~5%, and is grappling with a temporary retailer inventory reset. With a market cap near $11.7B and free cash flow of $778M, the risk/reward favors a mid-term swing long if management executes margin recovery and consumption stabilizes. Entry $96.60, stop $88.00, target $115.00 for a 45-trading-day trade…
Nike is trading near its recent low with RSI in the high-30s, positive MACD momentum, and a 3.6% dividend yield. The combination of attractive yield, improving category trends and a tight short-interest backdrop make a controlled long trade appealing: entry $45.00, stop $41.50, target $52.00 over a mid-term (45 trading days) horizon.
Nvidia's datacenter dominance and software stack are re-pricing the company's earnings trajectory away from a classic semiconductor cycle. With a $5.24 trillion market cap, 79%+ revenue growth expected into May earnings, and blockbuster free cash flow, this is a trade to own into AI infrastructure momentum — if you accept near-term volatility from …
Alaska Air (ALK) reported a Q1 loss and warned of roughly $600 million of extra fuel cost pressure for Q2. The shares are trading near $40 with negative free cash flow, elevated leverage and a stretched current ratio. With crude prices and geopolitical risk still the dominant driver, this is a trade to sell the bounce: entry $40.00, stop $44.00, ta…
Smurfit-WestRock (WRK) is my favorite long-term pick right now. The combination of scale, structural demand for sustainable packaging, and the ability to drive synergies make this a compelling risk-reward into the next 6-9 months. This trade plan lays out a concrete entry, stop and target with catalysts and what would change my view.
Doximity (DOCS) has been punished by headline risk and a software selloff even as its physician network and high margins remain intact. Trading near $24.57 and a market cap around $4.6B, DOCS offers a favorable risk/reward for a mid-term swing: entry at $24.57, stop at $20.55, target $36.00 over ~45 trading days.
Aktis Oncology is a clinical-stage radiopharmaceutical company with a deep-pocketed IPO and a pipeline built around miniprotein radioconjugates designed to reach large patient populations. Recent IND clearance activity and first clinical imaging/dosimetry data for AKY-2519 set up a series of binary catalysts. At a market cap near $990M and with ~ $…
Joby Aviation is a pure-play eVTOL with clear commercialization milestones — NYC demo flights and a confirmed Dubai launch in 2026 — but the balance sheet, negative cash flow and a premium valuation make shares a speculative long. Buy on a measured pullback, size tightly, and treat this as a catalyst-driven swing trade: certification, early revenue…
Build-A-Bear (BBW) looks attractively valued relative to its cash flow and profitability: no debt, $39.5M in free cash flow and a trailing P/E under 10. That said, tariff pressure, uneven e-commerce trends and concentrated seasonality create real execution risk. This trade idea lays out a mid-term (45 trading days) tactical long with exact entry, s…
Lotus Creek Exploration (LTCEF) is an OTC exploration company trading at $2.85 with clear near-term technical momentum and elevated short interest. This trade idea outlines a disciplined long: entry $2.85, stop $2.20, target $4.00, horizon mid term (45 trading days). The thesis rests on price trading above its moving averages, bullish MACD, and sho…
Navitas (NVTS) sits at the intersection of gallium nitride (GaN)/silicon carbide (SiC) power conversion and a surging demand cycle for higher-voltage, higher-efficiency data center infrastructure. The stock is volatile and richly valued, but recent product shifts to 800V SiC platforms and sustained retail interest create a window for a tactical lon…
Veradermics' positive VDPHL01 dataset materially improves the late-stage pipeline narrative and creates a tactical entry opportunity. With clinical risk reduced, upside from partnership/label expansion and a re-rating of the franchise could drive a multi-bagger move. Trade idea includes clear entry, stop, and target with a 180-trading-day horizon a…
AECOM (ACM) has suffered two earnings-driven pullbacks this year that sent the stock to fresh lows. Fundamentals remain intact - $615.95M free cash flow, $12.29B enterprise value and consensus upside in 2026 guidance - while technicals point to an oversold entry. This trade idea lays out a mid-term, defined-risk long with concrete entry, stop and t…
Qualcomm's combination of low-power AI silicon, entrenched OEM relationships, and recurring licensing revenue makes it uniquely positioned to capture a large slice of the next phase of AI adoption - the shift from cloud-only to a cloud-to-edge continuum. This trade targets a mid-term re-rating as product wins and design-ins translate into visible r…
S&P Global punched back this earnings season. Fundamentals - strong free cash flow, solid ROE, and lowish leverage - plus bullish technical momentum argue for a mid-term long. This is a trade idea with a clear entry at $444.00, stop at $405.00 and a primary target of $520.00 over roughly 45 trading days.
Capri Holdings (CPRI) is showing the first signs of stabilization after a bruising multi-year reset. A potential cash infusion from the Versace sale, improving technical momentum and a reasonable EV/EBITDA multiple create a tactical long opportunity. The company still carries heavy leverage, negative cash flow and legal overhangs — this trade is a …
KEYENCE (KYCCF) shows accelerating price momentum, improving moving averages and a sharp rise in short interest that together argue for a tactical long position. Pairing momentum with a prudent stop keeps risk controlled while giving room for the company’s product cycle and capital return clarity to play out over the next 180 trading days.
Universal Electronics (UEIC) trades at a tiny market cap (~$54M) but produces meaningful free cash flow (~$19.8M). The balance sheet is light on debt and multiples are compressed (P/S 0.14, P/B ~0.36, EV/EBITDA 5). That combination makes UEIC a tactical long: multiple catalysts could spark a rerating while risk controls keep downside manageable.
Travelers is not a high-flying growth story, but at a current price near $311 it offers attractive valuations (PE ~9, PB ~2.0), strong underwriting economics, and a healthy capital-return profile. This trade idea targets a measured swing over the next 45 trading days with defined risk controls and a bias toward owning the name into upcoming dividen…
Arm is trading off a recent pullback while momentum and fundamental drivers around agentic AI remain intact. The company’s shift toward in-house chip design and a wide licensing footprint position it to capture a structural increase in CPU demand from hyperscalers. This trade idea lays out a long entry at $197.55, a stop at $165.00 and a $275.00 ta…
Iovance Biotherapeutics (IOVA) is a buy for a mid-term swing trade. With a recent uptick in commercial traction for Amtagvi (lifileucel), a resolved near-term regulatory binary in a biotech peer that drew capital and attention, and a reasonable enterprise valuation near $1.25B, the stock offers asymmetric upside over the next 45 trading days. Entry…
Investors are fretting about Oracle's elevated capital spending as the company doubles down on data centers and AI infrastructure. That fear is understandable, but it may be priced in. If cloud revenue and software subscription momentum hold, incremental CapEx could be a one-time drag that unlocks outsized recurring revenue and margin expansion ove…
AllianceBernstein units recently reset distributions to $0.96 per share (quarterly), pushing the yield to roughly 10% at today's $38.05 price. The underlying money-manager fundamentals - $3.25 EPS, P/E ~11.7, ROE ~24% and no debt - make a long trade attractive for income-sensitive investors willing to accept near-term distribution volatility. This …
Circle Internet Group plunged on draft legislation and analyst downgrades that threaten its yield business on USDC. Fundamentals still show scale: $2.75B revenue in 2025 (64% y/y growth per coverage), $331M free cash flow and a $22B enterprise value. This idea treats the pullback as a tradeable dip: enter on weakness, use a tight stop, and target a…
SBIO offers concentrated exposure to small-cap biotech names in Phase II/III trials. The ETF's recovery from a 52-week low, a modest yield, and a shallow float create an attractive asymmetric trade. I recommend a long with a clear entry, stop and target over a 180 trading-day horizon while respecting heightened volatility and shorting activity.
